By Amandine flour
Published on 29 Mar 21 @ 12:28 pm
updated on 29 Mar 21 at 12:28
–
In Nancy, the CHRU and the Lorraine Cancer Institute are trying to avoid hospitalization for certain patients with Covid-19. How? ‘Or’ What ? Through treatment with dual monoclonal antibody therapy.
The two establishments are among the first sites to administer these innovative treatments offered by the Roche and Lilly laboratories.
Who can benefit from this treatment?
In a joint press release, the two health establishments indicate that these drugs are intended for “Treatment of mild to moderate symptomatic forms of Covid-19 in adults who are not hospitalized and at high risk of progressing to a severe form”.
This concerns in particular patients with an immunity deficit linked to a pathology or to treatments, patients at risk of complications and patients over 80 years of age.
To maximize the chances of success, treatment should be given within five days of the onset of the first symptoms.
How to benefit from it?
It is the SAMU or the doctor who send the patient who can benefit from the treatment to the CHRU of Nancy or to the Cancer Institute.
When it is admitted that he can receive the drugs, he is redirected to one of the two establishments according to his situation, with a view to outpatient treatment.
The Nancy CHRU welcomes and takes care of all patients with an immunity deficit linked to a pathology or treatment as well as patients with malignant hemopathies and tumors of the central nervous system.
The Cancer Institute only takes care of patients undergoing chemotherapy.
–
